FDMT - CIK 0001650648
4D Molecular Therapeutics, Inc. (FDMT) reported net income of -$140.11M for fiscal year 2025, as filed in its audited annual report with the SEC.
| Fiscal year | Net Income | Change |
|---|---|---|
| FY 2025 | -$140.11M | +12.9% |
| FY 2024 | -$160.87M | -59.5% |
| FY 2023 | -$100.84M | +6.2% |
| FY 2022 | -$107.49M | -50.7% |
| FY 2021 | -$71.32M | -25.8% |
| FY 2020 | -$56.69M | -15.0% |
| FY 2019 | -$49.31M | - |
4D Molecular Therapeutics, Inc. (FDMT) reported net income of -$140.11M for fiscal year 2025, as filed in its audited annual report with the SEC.
Between fiscal 2019 and fiscal 2025, 4D Molecular Therapeutics, Inc.'s net income declined from -$49.31M to -$140.11M.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.